Clinical Trials List
2010-12-20 - 2014-12-20
Phase III
Terminated6
ICD-10E78.0
Pure hypercholesterolemia
ICD-9272.0
Pure hypercholesterolemia
-
Trial Applicant
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 黃金洲 Division of Cardiovascular Diseases
- Po-Hsun Huang Division of Cardiovascular Diseases
- Liang-Yu Lin Division of Cardiovascular Diseases
- Tao-Cheng Wu Division of Cardiovascular Diseases
- Wen-Chung Yu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 趙嘉倫 Division of Cardiovascular Diseases
- HUNG-JU LIN Division of Cardiovascular Diseases
- 蘇大成 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 洪國竣 Division of Cardiovascular Diseases
- I-Chang Hsieh Division of Cardiovascular Diseases
- 王朝永 Division of Cardiovascular Diseases
- 陳俊吉 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 蕭峰青 Division of Endocrinology
- 謝昌勳 Division of Endocrinology
- 吳令怡 Division of Endocrinology
- Chih-Tsueng He Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ting-Hsing Chao Division of Cardiovascular Diseases
- Shih-Hung Chan Division of Cardiovascular Diseases
- 李貽恆 Division of Cardiovascular Diseases
- Ju-Yi Chen Division of Cardiovascular Diseases
- Po-Sheng Chen Division of Cardiovascular Diseases
- Wei-Chuan Tsai Division of Cardiovascular Diseases
- 李志展 Division of Cardiovascular Diseases
- 李威廷 Division of Cardiovascular Diseases
- Yi-Heng Li Division of Cardiovascular Diseases
- Cheng-Han Lee Division of Cardiovascular Diseases
- Yen-Wen Liu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 林禮賢 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
200 participants
-
Global
200 participants